Expression of serum CEA,CA19-9,and β2-MG predicts the therapeutic effect and survival of patients with bladder cancer undergoing intravesical chemotherapy with pirarubicin
Objective To explore the relationship between the levels of serum carcinoembryonic antigen(CEA),cancer antigen 199(CA19-9),andβ2-microglobulin(β2-MG)in patients with bladder cancer and the therapeutic effect and survival of pirarubicin intravesical chemotherapy for bladder canc-er.Methods A total of 98 patients with bladder cancer who received pirarubicin intravesical chemo-therapy at Nanyang First People's Hospital from March 2021 to April 2023 were selected as the study subjects.They were divided into an effective chemotherapy group(52 cases)and an ineffective chemo-therapy group(46 cases)based on the chemotherapy outcomes.The clinical data and serum levels of CEA,CA19-9,andβ2-MG were compared between the two groups.Univariate and multivariate analy-sis,survival analysis,and Cox regression analysis were performed.Results The levels of serum CEA,CA19-9,and β2-MG in the effective chemotherapy group were lower than those in the ineffective chemotherapy group(P<0.001).Further multivariate logistic regression analysis showed that serum CEA level was an independent risk factor for chemotherapy effectiveness and survival.Patients with high CEA expression had poor chemotherapy outcomes and prognosis.Serum CA19-9 andβ2-MG lev-els were also associated with chemotherapy outcomes but were not independent influencing factors.Conclusion Serum CEA level is an important indicator for predicting the therapeutic effect and surviv-al of intravesical chemotherapy for bladder cancer.It is recommended to detect serum CEA,CA19-9,andβ2-MG levels in patients with bladder cancer to guide the formulation of individualized treatment plans.
万方数据
